Shares of Heska Corp (NASDAQ:HSKA) have been given a consensus recommendation of “Hold” by the seven brokerages that are covering the stock. Four investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $90.50.
Several research analysts recently issued reports on the stock. B. Riley reissued a “neutral” rating and set a $70.50 target price on shares of Heska Corp in a report on Thursday, February 23rd. Benchmark Co. reissued a “buy” rating and set a $106.00 target price (up previously from $100.00) on shares of Heska Corp in a report on Wednesday, March 1st. Zacks Investment Research raised shares of Heska Corp from a “hold” rating to a “buy” rating and set a $102.00 target price for the company in a report on Thursday, March 2nd. Finally, CL King cut shares of Heska Corp from a “buy” rating to a “neutral” rating in a report on Thursday, January 26th.
In related news, EVP Rod Lippincott sold 5,157 shares of the firm’s stock in a transaction on Thursday, March 9th. The shares were sold at an average price of $97.87, for a total transaction of $504,715.59. Following the sale, the executive vice president now owns 10,513 shares in the company, valued at $1,028,907.31. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Kevin S. Wilson sold 8,000 shares of the firm’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $90.00, for a total transaction of $720,000.00. Following the sale, the chief executive officer now owns 110,000 shares in the company, valued at approximately $9,900,000. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,865 shares of company stock worth $1,808,433. 15.30% of the stock is owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Two Sigma Securities LLC purchased a new stake in Heska Corp during the third quarter valued at approximately $244,000. Louisiana State Employees Retirement System purchased a new stake in Heska Corp during the first quarter valued at approximately $262,000. BlackRock Inc. raised its stake in Heska Corp by 6.2% in the third quarter. BlackRock Inc. now owns 5,413 shares of the medical research company’s stock valued at $295,000 after buying an additional 318 shares in the last quarter. Sheets Smith Wealth Management purchased a new stake in Heska Corp during the third quarter valued at approximately $412,000. Finally, Elkfork Partners LLC purchased a new stake in Heska Corp during the fourth quarter valued at approximately $495,000. Institutional investors own 77.40% of the company’s stock.
Shares of Heska Corp (NASDAQ:HSKA) traded up 0.42% during trading on Tuesday, reaching $105.17. 64,829 shares of the company were exchanged. The firm has a market capitalization of $741.66 million, a PE ratio of 73.55 and a beta of 0.83. The company’s 50-day moving average is $98.37 and its 200 day moving average is $76.39. Heska Corp has a 1-year low of $26.25 and a 1-year high of $107.18.
Heska Corp (NASDAQ:HSKA) last issued its earnings results on Tuesday, February 28th. The medical research company reported $0.46 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.09. Heska Corp had a net margin of 7.55% and a return on equity of 10.46%. The firm earned $39.50 million during the quarter, compared to analysts’ expectations of $34.56 million. The business’s revenue for the quarter was up 32.6% on a year-over-year basis. Equities research analysts expect that Heska Corp will post $1.70 EPS for the current fiscal year.
About Heska Corp
Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company focuses on the canine and feline companion animal health markets. Its segments include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.
Receive News & Ratings for Heska Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp and related companies with MarketBeat.com's FREE daily email newsletter.